CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Akebia Therapeutics Q3 revenue misses on lower Auryxia sales

By Reuters News


Overview

  • U.S. kidney disease drugmaker's Q3 revenue fell, missing analyst expectations

  • Q3 net loss widened and missed analyst estimates

  • Company attributed revenue decline to lower Auryxia sales amid generic competition and pricing pressure


Outlook

  • Company expects Auryxia revenues to continue decreasing in 2026 due to generic competition and pricing pressure

  • Akebia anticipates Vafseo access will expand in 2027 beyond TDAPA-only patients to nearly all eligible patients

  • Company expects to report initial data from Phase 2 ebribafusp alfa trial in 2027


Result Drivers

  • VAFSEO INVENTORY REDUCTION - Co said Q3 Vafseo revenue was impacted by inventory reduction at its largest customer and market dynamics as TDAPA expiration approaches

  • AURYXIA GENERIC COMPETITION - Co said Auryxia revenue continued to decline due to generic competition and pricing pressure

  • INCREASED R&D SPEND - Higher research and development expenses driven by increased clinical trial activity for pipeline assets


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$36.90 mln

$46.94 mln (6 Analysts)

Q3 Loss Per Share

Miss

$0.05

$0.04 (6 Analysts)

Q3 Net Loss

Miss

$14.35 mln

$9.63 mln (5 Analysts)

Q3 Loss From Operations

Miss

-$11.46 mln

-$6.68 mln (5 Analysts)

Q3 Loss Per Basic Share

$0.05

Q3 Operating Expenses

$42.003 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Akebia Therapeutics Inc is $4.00, about 475.8% above its November 4 closing price of $0.69


Reuters Recommended Reads

  • Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

  • Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

  • Nov 3 - Rhythm Pharma Q3 net loss narrower than estimated on IMCIVREE demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.